WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation ABUS, an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray, Arbutus' President and CEO, will present at the following conferences in May 2019:
| UBS Global Healthcare Conference – New York | Monday, May 20, 2019, 1:00 PM ET |
| Â | Â |
| RBC Capital Markets Healthcare Conference – New York | Tuesday, May 21, 2019, 11:00 AM ET |
Live webcasts of the presentations can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com. A replay of the webcasts will be available for 90 days following the live presentations.
About Arbutus
Arbutus Biopharma Corporation is a publicly-traded ABUS biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Mark Murray
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com
Pam Murphy
Investor Relations Consultant
Phone: 604-419-3200
Email: ir@arbutusbio.com
Â
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
